Cancers最新文献

{"title":"Hepatocellular Carcinoma After HCV Eradication with Direct-Acting Antivirals: A Reappraisal Based on New Parameters to Assess the Persistence of Risk.","authors":"Eduardo Fassio, Luis Colombato, Gisela Gualano, Soledad Perez, Miguel Puga-Tejada, Graciela Landeira","doi":"10.3390/cancers17061018","DOIUrl":"10.3390/cancers17061018","url":null,"abstract":"<p><p>Approximately 95% of patients with chronic hepatitis C achieve viral eradication through direct-acting antiviral (DAA) treatment. Ensuing clinical benefits include halting liver fibrosis, thereby reducing the need for liver transplantation, and decreasing both liver-related and overall mortality. It is well established that, although ameliorated, the risk of developing hepatocellular carcinoma (HCC) persists, particularly among patients with pre-treatment advanced fibrosis/cirrhosis. Current guidelines recommend indefinite HCC surveillance in these patients. However, a recent Markov model evaluation shows that HCC surveillance is cost-effective only for patients with cirrhosis but not so for those with F3 fibrosis, a finding which points out the need to better define the risk of HCC in hepatitis C patients after cure and further characterize pre- and post-treatment factors that might affect the incidence of HCC in this setting. We reviewed the literature analyzing this aspect. Here we summarize the main findings: male gender and older age are independent predictors of increased risk of post-cure HCC development. Moreover, non-invasive tests for hepatic fibrosis, namely FIB4, APRI, and liver stiffness, measured before and after treatment and their post-therapy change, contribute to better stratifying the risk of HCC occurrence. Furthermore, low serum albumin, as well as an AFP above 7 ng/mL prior to and after DAA therapy, also constitute independent predictors of HCC development. Considering these findings, we propose to classify patients with HCV viral eradication and advanced fibrosis/cirrhosis into groups of low, medium, or high risk of HCC and to adopt adequate surveillance strategies for each group, including protocols for abbreviated magnetic resonance imaging (MRI) for those at the highest risk.</p>","PeriodicalId":9681,"journal":{"name":"Cancers","volume":"17 6","pages":""},"PeriodicalIF":4.5,"publicationDate":"2025-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11940336/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143729002","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Predicting Pathogenic Variants of Breast Cancer Using Ultrasound-Derived Machine Learning Models.","authors":"Nicoleta Zenovia Antone, Roxana Pintican, Simona Manole, Liviu-Andrei Fodor, Carina Lucaciu, Andrei Roman, Adrian Trifa, Andreea Catana, Carmen Lisencu, Rares Buiga, Catalin Vlad, Patriciu Achimas Cadariu","doi":"10.3390/cancers17061019","DOIUrl":"10.3390/cancers17061019","url":null,"abstract":"<p><p><b>Background:</b> Breast cancer (BC) is the most frequently diagnosed cancer in women and the leading cause of cancer-related deaths in women globally. Carriers of P/LP variants in the <i>BRCA1</i>, <i>BRCA2</i>, <i>TP53</i>, <i>PTEN</i>, <i>CDH1</i>, <i>PALB2</i>, and <i>STK11</i> genes have an increased risk of developing BC, which is why more and more guidelines recommend prophylactic mastectomy in this group of patients. Because traditional genetic testing is expensive and can cause delays in patient management, radiomics based on diagnostic imaging could be an alternative. This study aims to evaluate whether ultrasound-based radiomics features can predict P/LP variant status in BC patients. <b>Methods</b>: This retrospective study included 88 breast tumors in patients tested with multigene panel tests, including all seven above-mentioned genes. Ultrasound images were acquired prior to any treatment, and the tumoral and peritumoral areas were used to extract radiomics data. The study population was divided into P/LP and non-P/LP variant groups. Radiomics features were analyzed using machine learning models, alone or in combination with clinical features, with the aim of predicting the genetic status of BC patients. <b>Results</b>: We observed significant differences in radiomics features between P/LP- and non-P/LP-variant-driven tumors. The developed radiomics model achieved a maximum mean accuracy of 85.7% in identifying P/LP variant carriers. Including features from the peritumoral area yielded the same maximum accuracy. <b>Conclusions</b>: Radiomics models based on ultrasound images of breast tumors may provide a promising alternative for predicting P/LP variant status in BC patients. This approach could reduce dependence on costly genetic testing and expedite the diagnostic process. However, further validation in larger and more diverse populations is needed.</p>","PeriodicalId":9681,"journal":{"name":"Cancers","volume":"17 6","pages":""},"PeriodicalIF":4.5,"publicationDate":"2025-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11940624/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143728919","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bone Marrow CD34+/lin- Cells of Patients with Chronic-Phase Chronic Myeloid Leukemia (CP-CML) After 12 Months of Nilotinib Treatment Exhibit a Different Gene Expression Signature Compared to the Diagnosis and the Corresponding Cells from Healthy Subjects.","authors":"Alessandra Trojani, Ester Pungolino, Barbara Di Camillo, Luca Emanuele Bossi, Cassandra Palumbo, Mariella D'adda, Alessandra Perego, Mauro Turrini, Chiara Elena, Lorenza Maria Borin, Alessandra Iurlo, Simona Malato, Francesco Spina, Maria Luisa Latargia, Pierangelo Spedini, Salvatore Artale, Michela Anghilieri, Maria Cristina Carraro, Cristina Bucelli, Alessandro Beghini, Roberto Cairoli","doi":"10.3390/cancers17061022","DOIUrl":"10.3390/cancers17061022","url":null,"abstract":"<p><strong>Background: </strong>Chronic-Phase Chronic Myeloid Leukemia (C-PCML) is defined by the presence of the <i>BCR-ABL1</i> fusion gene, which encodes a tyrosine kinase protein that drives the uncontrolled proliferation and survival of leukemic stem cells (LSCs). Nilotinib, a tyrosine kinase inhibitor, targets the activity of BCR-ABL1 by reducing aberrant signaling pathways, which drive the regeneration of LSCs. Despite nilotinib's action, a population of resilient LSCs persist in the bone marrow (BM) and can indeed drive relapse and progression in CML patients.</p><p><strong>Methods: </strong>Our study investigated the gene expression profiling (GEP) of BM CD34+/lin- cells from 79 CP-CML patients at diagnosis, compared to the BM CD34+/lin- cells from the same patients after 12 months of nilotinib treatment and to the normal counterpart cells from 10 donors (CTRLs).</p><p><strong>Results: </strong>GEP analyses identified 3012 significantly differentially expressed genes across these comparisons. Among these, we focused on certain key genes associated with eight crucial KEGG pathways: CML, cell cycle, JAK-STAT, PI3K-Akt, MAPK, Ras, NF-kB, and ABC transporters. Within these pathways, we observed the up-regulation of several genes at diagnosis compared to both 12 months of nilotinib treatment and the CTRLs.</p><p><strong>Conclusions: </strong>We observed that certain transcriptome features present at diagnosis persisted after 12 months of nilotinib treatment, compared to CTRLs. This suggests that nilotinib may exert selective pressure, potentially supporting the survival and self-renewal of LSCs. Future insights into these pathways could help identify therapeutic targets to improve outcomes in CML.</p>","PeriodicalId":9681,"journal":{"name":"Cancers","volume":"17 6","pages":""},"PeriodicalIF":4.5,"publicationDate":"2025-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11940473/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143728705","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Effect of Lifestyle on the Quality of Life of Vulvar Cancer Survivors.","authors":"Marleen S Boonstra, Anke Smits, Viktor Cassar, Ruud L M Bekkers, Yvonne Anderson, Nithya Ratnavelu, Tineke F M Vergeldt","doi":"10.3390/cancers17061024","DOIUrl":"10.3390/cancers17061024","url":null,"abstract":"<p><p><b>Introduction</b>: Vulvar cancer affects approximately 47,000 women annually worldwide. With most studies focusing on oncological outcomes, quality of life is often overlooked. There is a lack of knowledge on the influence of modifiable factors such as lifestyle on the quality of life of vulvar cancer survivors. This study evaluated the association between lifestyle factors and the quality of life of vulvar cancer survivors. <b>Methods</b>: This was a cross-sectional survey study of women who received surgical treatment for vulvar cancer ≥FIGO stage 1B at the Northern Gynecological Oncology Centre, UK, between 2013 and 2022. Baseline and clinical characteristics were collected from patient records. Godin Leisure-Time Exercise questionnaires were used to assess physical activity. BMI was assessed using self-reported height and weight. Quality of life was measured using the validated European Organization for Research and Treatment of Cancer Core Quality of Life Questionnaire (EORTC QLQ-C30) and the vulvar cancer-specific module (VU-34). An analysis was performed using Mann-Whitney-U and Kruskal-Wallis tests. <b>Results</b>: Of the 299 women, 139 were eligible for participation, of whom 58 participated (41.7%). Twenty participants had a sedentary (40.8%), eight a moderately active (16.3%), and seventeen an active (34.7%) lifestyle. Active participants reported higher overall quality of life and higher functioning in all domains but not for vulvar-related symptoms or sexual functioning. Forty-nine participants disclosed their BMI, which was not associated with quality of life outcomes. <b>Conclusions</b>: A higher level of physical activity was associated with higher quality of life. No association was found between BMI and quality of life.</p>","PeriodicalId":9681,"journal":{"name":"Cancers","volume":"17 6","pages":""},"PeriodicalIF":4.5,"publicationDate":"2025-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11940754/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143729062","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Describing the Core Attributes and Impact of Comprehensive Cancer Centers Internationally: A Chronological Scoping Review.","authors":"Carla Thamm, Elise Button, Jolyn Johal, Reegan Knowles, Catherine Paterson, Michael T Halpern, Andreas Charalambous, Alexandre Chan, Sanchia Aranda, Carolyn Taylor, Raymond J Chan","doi":"10.3390/cancers17061023","DOIUrl":"10.3390/cancers17061023","url":null,"abstract":"<p><p><b>Background/Objectives</b>: Comprehensive cancer centers (CCCs) remain at the forefront of cancer control efforts. Limited clarity and variation exist around the models, scope, characteristics, and impacts of CCCs around the globe. This scoping review systematically searched and synthesized the international literature, describing core attributes and anticipated and realized impacts of CCCs, detailing changes over time. <b>Methods</b>: Searches for English language sources were conducted across PubMed, Cochrane CENTRAL, Epistemonikos, and the gray literature from January 2002 to April 2024. Data were extracted and appraised by two authors. Results were narratively synthesized. <b>Results</b>: Of 3895 database records and 843 gray literature sources screened, 81 sources were included. Papers were predominantly opinion-based, from the USA and Europe, and published between 2011 and 2020. Internationally, the interconnected attributes of CCCs included (1) clinical service provision; (2) research, data, and innovation; (3) education and clinical support; (4) networks and leadership; (5) health equity and inclusiveness; and (6) accountability and governance. Largely anticipated impacts were synergistic and included delivery of optimal, person-centered, complex care; development of a highly qualified cancer workforce; greater research activity and funding; effective, strategic alliances; and reduction in cancer-related inequalities. Limited evidence was found demonstrating measurable broad outcomes of CCCs. The early literature highlighted the establishment, development, and accreditation of CCCs. The ongoing literature has reflected the evolution of cancer care, key areas for growth, and limitations of CCCs. Recently, the CCC literature has increased exponentially and focused on the need for CCCs to drive networks and leadership to address health equity and inclusiveness. <b>Conclusions</b>: Results suggest that CCCs are yet to reach their full potential, with future efforts ideally focusing on accountability, effective networking, and health equity at a local, national, and international level. CCCs must generate evidence of impact, and continue to evolve in line with contemporary healthcare, to fulfil their role in cancer control efforts.</p>","PeriodicalId":9681,"journal":{"name":"Cancers","volume":"17 6","pages":""},"PeriodicalIF":4.5,"publicationDate":"2025-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11940407/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143728992","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction: Zossou et al. Radiomics-Based Classification of Tumor and Healthy Liver on Computed Tomography Images. <i>Cancers</i> 2024, <i>16</i>, 1158.","authors":"Vincent-Béni Sèna Zossou, Freddy Houéhanou Rodrigue Gnangnon, Olivier Biaou, Florent de Vathaire, Rodrigue S Allodji, Eugène C Ezin","doi":"10.3390/cancers17061021","DOIUrl":"10.3390/cancers17061021","url":null,"abstract":"<p><p><b>Text Correction</b> [...].</p>","PeriodicalId":9681,"journal":{"name":"Cancers","volume":"17 6","pages":""},"PeriodicalIF":4.5,"publicationDate":"2025-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11941315/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143728807","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Emerging Potential of Metabolomics in Thyroid Cancer-A Comprehensive Review.","authors":"Sonam Kumari, Andrew Makarewicz, Joanna Klubo-Gwiezdzinska","doi":"10.3390/cancers17061017","DOIUrl":"10.3390/cancers17061017","url":null,"abstract":"<p><p>Thyroid cancer is a very common endocrine system malignancy. Nevertheless, a dearth of precise markers makes it challenging to apply precision medicine to thyroid cancer. The limitations of standard diagnosis techniques (fine-needle aspiration biopsy), such as indeterminate cases and inaccuracies in distinguishing between different types of cancers, lead to unnecessary surgeries and thus warrant the development of more discriminatory biomarkers to improve the accuracy of existing diagnostic and prognostic techniques. Moreover, individualized therapies for thyroid cancer are necessary to avoid overtreatment of indolent lesions and undertreatment of high-risk progressive disease. As thyroid cancer metabolic signatures are associated with disease aggressiveness and responsiveness to therapy, metabolomics has been recently used for diagnostic and prognostic biomarker discovery. This strategy has enabled the detection of several metabolites from tissue samples or biofluids to facilitate the classification of disease aggressiveness and to potentially assist in individualized therapies. In this review, we summarize the utilization and potential of metabolomics in thyroid cancer.</p>","PeriodicalId":9681,"journal":{"name":"Cancers","volume":"17 6","pages":""},"PeriodicalIF":4.5,"publicationDate":"2025-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11940765/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143729059","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Investigating Intensity and Percentage of p53 Nuclear Expression in Prostate Cancer: Findings from a Cohort of U.S. Military Veterans.","authors":"William R Gesztes, Coen J Lap, Rithika Rajendran, Maryam M Dalivand, Guoqing Diao, Shanshan Liu, Maneesh Jain, Victor E Nava","doi":"10.3390/cancers17061004","DOIUrl":"10.3390/cancers17061004","url":null,"abstract":"<p><strong>Background: </strong>Next-generation sequencing has revealed <i>TP53</i> alterations in localized prostate cancer (PCa), suggesting growing clinical potential for p53 immunohistochemistry (IHC). Prior research supports the use of IHC for the detection of p53 overexpression to predict the presence of <i>TP53</i> alterations known to be associated with adverse outcomes. However, to reach a consensus definition of p53 overexpression in PCa, further insights are needed. This study aimed to compare two fundamental approaches of evaluating p53 expression across a variety of specimens regarding PCa progression.</p><p><strong>Methods: </strong>This study included 84 patients (75% self-identified as African American) diagnosed with PCa between 1996 and 2021 at the DC VA Medical Center. Representative sections of core biopsies, radical prostatectomies, transurethral prostate resections, and metastatic deposits were examined. p53 nuclear expression was scored according to the highest intensity observed (0, 1+, 2+, 3+) and the percentage (0%, <1%, 1-5%, >5%) of tumor cells expressing any level of intensity in the aggregate tumor area. All slides were reviewed by two independent pathologists. Pertinent clinical data were collected.</p><p><strong>Results: </strong>A total of 34 patients (40%) exhibited p53 nuclear expression, of which 18 (21%) showed the maximum (3+) intensity. The presence of maximum intensity, regardless of percentage, was found to be associated with Grade Group (<i>p</i> < 0.001), higher PSA at biopsy (<i>p</i> < 0.001), BCR (<i>p</i> < 0.001) and metastasis (<i>p</i> < 0.001). Importantly, maximum p53 intensity was identified only in patients who developed metastatic disease.</p><p><strong>Conclusions: </strong>Maximum (3+) p53 nuclear intensity of any percentage is highly associated with disease progression in PCa, suggesting that optimal determination of p53 overexpression should incorporate intensity.</p>","PeriodicalId":9681,"journal":{"name":"Cancers","volume":"17 6","pages":""},"PeriodicalIF":4.5,"publicationDate":"2025-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11941523/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143728823","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long-Term Quality of Life and Functional Outcomes in Patients with Total Laryngectomy.","authors":"Maria Octavia Murariu, Eugen Radu Boia, Adrian Mihail Sitaru, Cristian Ion Mot, Mihaela Cristina Negru, Alexandru Cristian Brici, Delia Elena Zahoi, Nicolae Constantin Balica","doi":"10.3390/cancers17061011","DOIUrl":"10.3390/cancers17061011","url":null,"abstract":"<p><strong>Background: </strong>Laryngeal cancer affects quality of life (QoL), speech, and swallowing. Total laryngectomy (TL) causes severe impairments, while partial laryngectomy (PL) and chemoradiotherapy (CRT) preserve the organ but yield variable outcomes. This study assesses QoL, speech rehabilitation, swallowing, and social reintegration across these treatments.</p><p><strong>Methods: </strong>This prospective observational cohort study was conducted at the ENT Clinic, Victor Babeș University of Medicine and Pharmacy, Timișoara; recruitment was conducted between October 2019 and January 2024. Seventy-five patients diagnosed with laryngeal squamous cell carcinoma (LSCC) were initially enrolled but only 15 patients (20%) completed the 12-month follow-up, with an attrition rate of 80%. Tumor stages ranged from T1 to T4a, with TL patients having a higher proportion of advanced-stage disease (Stage III-IV: 76%) compared to PL (45%) and CRT (50%). Validated instruments, including the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Head and Neck Cancer (EORTC QLQ-H&N35), the Voice Handicap Index-30 (VHI-30), the Hospital Anxiety and Depression Scale (HADS), and the Dysphagia Outcome and Severity Scale (DOSS), were used to assess QoL, voice function, swallowing function, and psychological impact.</p><p><strong>Results: </strong>At 12 months, the global QoL score from the EORTC QLQ-H&N35 was lowest in TL patients (49.8 ± 10.9), significantly lower than both PL (61.2 ± 9.6, <i>p</i> = 0.002) and CRT (64.1 ± 7.8, <i>p</i> < 0.001). Post hoc Bonferroni analysis confirmed significant pairwise differences between TL vs. PL (<i>p</i> = 0.002) and TL vs. CRT (<i>p</i> < 0.001), while the difference between PL and CRT was non-significant (<i>p</i> = 0.14). TL patients had higher speech-related disability (VHI: 88.3 ± 12.6) and dysphagia prevalence (DOSS: 4.0 ± 1.2), with 16% remaining enteral feeding-dependent. Anxiety (HADS-A: 7.5 ± 2.9) and depression (HADS-D: 9.0 ± 3.2) were highest in TL patients, with 36% meeting clinical depression criteria at 12 months. Multivariable regression identified TL (OR = 3.92, 95% CI: 2.14-5.79, <i>p</i> < 0.001) and advanced tumor stage (OR = 2.85, 95% CI: 1.79-4.21, <i>p</i> = 0.002) as strong predictors of poor QoL. Kaplan-Meier analysis showed no significant OS differences (<i>p</i> = 0.12), but CRT patients had lower DFS (78%) compared to TL (82%) and PL (85%) (<i>p</i> = 0.048).</p><p><strong>Conclusions: </strong>TL patients experience the most significant impairments in QoL, speech, and social reintegration despite rehabilitation. CRT patients show higher recurrence rates but better QoL, while PL offers the best balance of function and survival. These findings highlight the need for long-term survivorship support tailored to treatment type.</p>","PeriodicalId":9681,"journal":{"name":"Cancers","volume":"17 6","pages":""},"PeriodicalIF":4.5,"publicationDate":"2025-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11941457/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143728866","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"IL-10-Directed Cancer Immunotherapy: Preclinical Advances, Clinical Insights, and Future Perspectives.","authors":"Adel G El-Shemi, Afnan Alqurashi, Jihan Abdullah Abdulrahman, Hanin Dhaifallah Alzahrani, Khawlah Saad Almwalad, Hadeel Hisham Felfilan, Wahaj Saud Alomiri, Jana Ahmed Aloufi, Ghadeer Hassn Madkhali, Sarah Adel Maqliyah, Jood Bandar Alshahrani, Huda Taj Kamal, Sawsan Hazim Daghistani, Bassem Refaat, Faisal Minshawi","doi":"10.3390/cancers17061012","DOIUrl":"10.3390/cancers17061012","url":null,"abstract":"<p><p>Interleukin-10 (IL-10) is a dimeric cytokine encoded by the <i>IL-10</i> gene on chromosome 1 [...].</p>","PeriodicalId":9681,"journal":{"name":"Cancers","volume":"17 6","pages":""},"PeriodicalIF":4.5,"publicationDate":"2025-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11940594/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143729006","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}